BNBehrang Nooralishahi

Behrang Nooralishahi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Behrang Nooralishahi has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Mehdi Dehghani Firoozabadi

    Tehran Heart Center, Cardiovascular Diseases Research Institute, Anesthesiology, Critical Care and Pain Research Center, Tehran University of Medical Science, Tehran, Iran, tums.ac.ir

    5 shared publications
  • Fatemeh Rezaei-Tazangi

    Department of Anatomy, School of Medicine Fasa University of Medical Sciences Fasa Iran

    3 shared publications
  • Hooman Naghashian

    School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Mohammadjavad Mehrabanian

    Assistant Professor, Anesthesia, Critical Care and Pain Management Research Center, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Afarin Zamani

    1 shared publication
  • Akbar Shafiee

    Tehran Heart Center, Cardiovascular Diseases Research Institute Tehran University of Medical Sciences Tehran Iran

    1 shared publication

Latest Publications

  • Open Access

    The Role of Ultra‐Low‐Dose Naloxone as an Additive in Anesthesia and Nerve Block: A Systematic Review

    by Mohammadjavad Mehrabanian, Behrang Nooralishahi, Mehdi Dehghani Firoozabadi, Mohammad Sahebjam, Yekta Ghane, Homayoun Pishraft‐Sabet, Nazila Heidari, Akbar Shafiee

    Background and Aims: In anesthesia and analgesia, opioids alone or in combination with local anesthetics (bupivacaine, lidocaine, and ropivacaine) have been investigated to prolong peripheral nerve blocks. Ultra‐low‐dose naloxone administration in local anesthetic solutions could lengthen sensory and motor blocks through enhanced opioid effects or direct antagonistic effects on the receptors. We aim to assess the role of ultra‐low‐dose naloxone as an additive in anesthesia duration, motor, and sensory block duration, visual analog scale (VAS) scores, opioid consumption, and the incidence of postoperative complications. Methods: A systematic search was conducted in PubMed/Medline, Ovid Embase, and Web of Science up to November 23rd, 2023, and 840 records were retrieved and screened. Accordingly, seven randomized controlled trials met the eligibility criteria and were included for data extraction. The National Institute of Health's (NIH) Quality Assessment Tool for Clinical Trials was used for critical appraisal of the studies. Results: The effects of ultra‐low‐dose naloxone on intravenous regional anesthesia and various nerve blocks (including axillary and supraclavicular brachial plexus, peribulbar, femoral, and intercostal nerve block) were assessed. The administration of naloxone at doses of 100 and 50 ng as an additive to bupivacaine, lidocaine, and ropivacaine was associated with longer postoperative analgesia, prolonged motor and/or sensory block, lower postoperative opioid or analgesic consumption, and lower VAS pain scores in several included studies. Besides, in most studies, postoperative complications did not significantly differ between the groups. Conclusion: The available evidence suggests that ultra‐low‐dose naloxone may be associated with prolonged postoperative analgesia and, in some studies, longer motor and/or sensory block duration and reduced postoperative opioid consumption. These findings should be interpreted as observations reported by individual studies rather than definitive treatment effects. Although no major safety concerns were identified, the available evidence is insufficient to establish the overall safety or efficacy of ultra‐low‐dose naloxone.

  • Open Access

    Determinants of the renal function after the coronary artery bypass grafting in chronic kidney disease patients: a prospective cohort study

    by Behrang Nooralishahi, Mohammad Rahmanian, Shiva Samavat, Kasra Jafari, Mohsen Nafar, Nooshin Dalili, Bahareh Haji Baratali, Reza Khademi, Mohammadsadegh Jafari, Reza Ghotbein

    Background: This study aims to evaluate renal outcomes and identify key factors influencing estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease(CKD) undergoing coronary artery bypass grafting (CABG). Methods: In a prospective cohort of 100 patients with CKD (mean age 65.5 years; 77% male; most in CKD stage 2 or 3), eGFR was measured at baseline, three months, and six months postoperatively. Generalized Estimating Equations (GEE) were applied to assess longitudinal changes in eGFR and associated predictors. Statistical analyses were performed using Stata 17. Results: Approximately 19% of patients experienced a > 30% decline in eGFR, while over 40% demonstrated improvement at six months. Advanced CKD stage, higher preoperative heart ejection fraction (EF), and longer anesthesia time were associated with greater eGFR decline. Conversely, higher preoperative hemoglobin (Hb) levels, elective surgery, and a history of cerebrovascular accident were associated with improved estimated eGFR trends. Conclusion: Several clinical and procedural factors influence postoperative renal function in CKD patients undergoing CABG. These findings support the development of targeted perioperative strategies to mitigate renal decline. Clinical trial registration: This study does not meet the criteria of a clinical trial and, therefore, was not registered in a clinical trial registry.

  • Open Access

    Oxycodone: A Pain‐Relieving Agent With Cardioprotective Properties Against Myocardial Ischemia–Reperfusion Injury

    by Mehdi Dehghani Firoozabadi, Behrang Nooralishahi, Fatemeh Rezaei-Tazangi

    In the realm of cardiovascular diseases, myocardial ischemia–reperfusion injury (MIRI) is known as one of the main life‐threatening conditions with significant morbidity and mortality. Although some therapeutic approaches, like pharmacological treatments and ischemic preconditioning, have been suggested for MIRI, offering a functional approach with high effectiveness for MIRI remains challenging. Recent studies have indicated that oxycodone, a semisynthetic opioid used to improve acute to chronic pain, may be cardioprotective against MIRI. The current experimental evidence showed that these protective influences can stem from the ability of oxycodone to regulate apoptosis, inflammation, and oxidative stress, as well as promote cardiovascular parameters (e.g., infarct size, cardiac function, and endothelial integrity). Hence, the main purpose of this narrative review study is to summarize and discuss the anti‐MIRI potential of oxycodone with a mechanistic insight. This narrative review was also conducted to hold promise for researchers and clinicians to consider and assess its clinical capacity for subjects suffering from this challenging disease.


  • Open Access

    Dehydrocorydaline can be a suitable candidate for analgesic purposes: a review on the current preclinical evidence

    by Mehdi Dehghani Firoozabadi, Behrang Nooralishahi, Fatemeh Rezaei-Tazangi

    Pain stands as one of the main factors related to human disability and suffering, with different classifications (e.g. acute/chronic, somatic/visceral, and malignant/non-malignant). The management of this factor is of great importance during the lifespan; however, the current suggested medications have not yet reflected sufficient effectiveness with minimum side effects. Therefore, applying an ideal strategy against conditions accompanied by pain is urgent. A growing body of evidence has recently highlighted that alkaloids as bioactive compounds with analgesic capacity can be effective in these conditions. Regarding this matter, dehydrocorydaline, a bioactive alkaloid derived from the tubers of Rhizoma Corydalis , has shown promising results in pain management in diseases, including Chronic constriction injury, bone cancer, sleep deprivation, and inflammatory pain. Also, dehydrocorydaline has been shown to exert different biological and pharmacological benefits, like anti-tumor, anti-inflammatory, anti-microbial, anti-viral, anti-nociceptive, and cardioprotective. Hence, in this literature review, we aimed to explore the potential of this alkaloid agent in these conditions with a mechanistic insight.


  • Open Access

    Analgesia and silymarin: What are the opportunities and challenges?

    by Mehdi Dehghani Firoozabadi, Behrang Nooralishahi, Fatemeh Rezaei-Tazangi

    Pain is an unpleasant sensory and emotional sensation about actual or possible tissue damage that can cause remarkable health and economic problems. For pain relief, analgesic drugs are commonly utilized; however, their prolonged use can cause different side effects from mild to severe stages. Therefore, discovering new and alternative choices for analgesic purposes is of importance. Hopeful evidence has shown that flavonoid compounds have various therapeutic and pharmacological potentials. Among these, silymarin, obtained from the milk thistle plant Silybum marianum , has addressed its competence in medicine, as demonstrated by its capacity against metabolic diseases, malignancies, inflammatory-related disorders, and organ toxicities. In the recent decade, some documents have stated the analgesic influences of silymarin, especially in some pathological situations like rheumatoid arthritis and neuropathic pain. Also, there is promising information regarding the possible synergistic effects of silymarin and some pharmacological or bioactive compounds. For these reasons, this narrative literature review aims to summarize and discuss the analgesic abilities of this flavonoid agent in pathological and nonpathological conditions and its interactions with other drugs with a focus on the involved mechanisms.

  • The Impact of Pregabalin Prescription as a Pre-Medication in Postoperative Pain Management Following Coronary Artery Bypass Grafting: A Systematic Review

    by Mohammadjavad Mehrabanian, Mehdi Dehghani Firoozabadi, Kaveh Hosseini, Mehdi Mehrani, Soheil Mansourian, Babak Kavand, Mehdi Rahab, Sahar Kianmehr, Mehrdad Malekshoar, Ashkan Taghizadeh Imani, et al.

    Bakcground & Aims: Advancements in coronary artery disease treatment via Coronary Artery Bypass Grafting (CABG) have been substantial, yet post-operative pain management remains a significant challenge. Pregabalin, known for its unique mechanism of action, has gained attention for its potential in reducing post-CABG pain. The complexity of post-CABG pain involves multiple ...

  • Open Access

    Evaluation of the correlation between end-tidal arterial carbon dioxide pressure based on mainstream capnography technique and arterial carbon dioxide pressure based on arterial blood gas analysis before and after cardiopulmonary bypass pump in children with non-cyanotic congenital heart defects

    by Ashkan Taghizadeh, Hooman Naghashian, Rojin Faroughi, Behrang Nooralishahi

    Background. It is still a matter of debate whether the evaluation of end-tidal carbon dioxide (ETCO2) using a capnography device allows the evaluation of non-invasive monitoring of arterial carbon dioxide pressure (PaCO2). The aim of this study was to compare the value of ETCO2 by direct mainstream and PaCO2 based on arterial gas analysis (ABG) before and after cardiopulmonary bypass pump in children with congenital heart defects. Methods. Twenty nine children who were candidates for elective cardiac surgery and were admitted to the Children's Medical Center were enrolled. Before and after cardiopulmonary bypass pump, ETCO2 was evaluated based on mainstream technique and PaCO2 based on arterial gas analysis. Results. The mean difference between ETCO2 and PaCO2 values before cardiopulmonary bypass pump was 3/68 ± 5/32 mm Hg, which considering that the difference of less than 5 mm Hg is clinically negligible, indicates an acceptable agreement between them. However, the mean difference between the two indices after cardiopulmonary bypass pump was 7/0 ± 6/85 mm Hg that accordingly, the difference between the two measured values after cardiopulmonary bypass will be clinically significant. Conclusion. Preoperative ETCO2 evaluation can provide a close prediction of PaCO2 levels, but after pumping, direct arterial sampling should be taken to accurately measure PaCO2 levels in non-cyanotic patients undergoing heart surgery. Practical Implications. When confronting with a child with non-cyanotic heart defect undergoing surgery, we suggest relying on capnography as a mirror of arterial blood pressure of carbon dioxide. However, capnography may not be as reliable during early post-bypass period in this group of patients and repeated arterial blood samples may be necessary.


  • Open Access

    The association between end-tidal carbon dioxide and arterial partial pressure of carbon dioxide after cardiopulmonary bypass pumping in cyanotic children

    by Behrang Nooralishahi, Rozhin Faroughi, Hooman Naghashian, Ashkan Taghizadeh, Mohammadjavad Mehrabanian, Mehdi Dehghani Firoozabadi

    Introduction: Evidence suggests the high capability of non-invasive assessment of the End-tidal carbondioxide (ETCO2) in predicting changes in arterial carbon dioxide pressure (PCO2) following major surgeries in children. We aimed to compare EtCO2 values measured by capnography with mainstream device and EtCO2 values assessed by arterial blood gas analysis before and after cardiopulmonary bypass pumping in cyanotic children. Methods: This cross-sectional study was performed on 32 children aged less than 12 years with ASA II suffering cyanotic heart diseases and undergoing elective cardiopulmonary bypass pumping. Arterial blood sample was prepared through arterial line before and after pumping and arterial blood gas (ABG)was analyzed. Simultaneously, the value of EtCO2 was measured by capnography with mainstream device. Results: A significant direct relationship was found between the changes in ETCO2 and arterialPCO2 (r = 0.529, P = 0.029) postoperatively. According to significant linear association between postoperative change in ETCO2 and arterial PCO2, we revealed a new linear formula between the two indices: ΔPCO2 = 0.89× ETCO2-0.54. The association between arterial PCO2 and ETCO2 remained significant adjusted for gender, age, and body weight. Conclusion: the value of ETCO2 can reliability estimate postoperative changes in arterial PCO2 in cyanotic children undergoing cardiopulmonary bypass pumping.